Cargando…

Genetic variants associated with metabolic dysfunction‐associated fatty liver disease in western China

INTRODUCTION: We aimed to confirm the association between some single nucleotide polymorphisms (SNPs) and metabolic dysfunction‐associated fatty liver disease (MAFLD) in western China. METHODS: A total of 286 cases and 250 healthy controls were enrolled in our study. All samples were genotyped for p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Shenling, An, Kang, Liu, Zhi, He, He, An, Zhenmei, Su, Qiaoli, Li, Shuangqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459258/ https://www.ncbi.nlm.nih.gov/pubmed/35881683 http://dx.doi.org/10.1002/jcla.24626

Ejemplares similares

Comparison of the diagnostic value between triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio in metabolic-associated fatty liver disease patients: a retrospective cross-sectional study
por: Liu, Zhi, et al.
Publicado: (2022)

Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients
por: Yang, Lidan, et al.
Publicado: (2022)

A nomogram for predicting metabolic steatohepatitis: The combination of NAMPT, RALGDS, GADD45B, FOSL2, RTP3, and RASD1
por: Liao, Shenling, et al.
Publicado: (2021)

Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population
por: Lee, Guan Huei, et al.
Publicado: (2020)

Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease
por: Zeng, Yuping, et al.
Publicado: (2022)

Association between Metabolic Dysfunction-associated Fatty Liver Disease and Cognitive Impairment
por: Yu, Qiang, et al.
Publicado: (2022)

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis
por: Dai, Yuzhao, et al.
Publicado: (2021)

Genetic variants in HFE are associated with non-alcoholic fatty liver disease in lean individuals
por: Sun, Zewen, et al.
Publicado: (2023)

Metabolic Dysfunction-Associated Fatty Liver Disease Increases the Risk of Gastroesophageal Reflux Symptoms
por: He, Yuan, et al.
Publicado: (2022)

Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China
por: Lei, Fang, et al.
Publicado: (2023)

Perspectives of general practitioners towards their supervisors over the past ten years in China
por: xin, Rao, et al.
Publicado: (2022)

Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China
por: Yuan, Xiaojie, et al.
Publicado: (2022)

Association of food intake with a risk of metabolic dysfunction-associated fatty liver disease: a cross-sectional study
por: Huang, Xian-Hua, et al.
Publicado: (2023)

MTP genetic variants associated with non-alcoholic fatty liver in metabolic syndrome patients
por: Gouda, Weaam, et al.
Publicado: (2017)

Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease
por: Miao, Lei, et al.
Publicado: (2022)

MBOAT7 rs641738 variant in metabolic-dysfunction-associated fatty liver disease and cardiovascular risk
por: Ismaiel, Abdulrahman, et al.
Publicado: (2023)

Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
por: Han, A Lum
Publicado: (2022)

Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population
por: Cai, Jinwei, et al.
Publicado: (2021)

Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
por: Song, Byeong Geun, et al.
Publicado: (2023)

What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD)
por: Bril, Fernando
Publicado: (2021)

Risk factors associated with postoperative complications after liver cancer resection surgery in western China
por: Hu, Yanjie, et al.
Publicado: (2021)

Low-Carbohydrate and Low-Fat Diet with Metabolic-Dysfunction-Associated Fatty Liver Disease
por: Hu, Chengxiang, et al.
Publicado: (2023)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease
por: Baratta, Francesco, et al.
Publicado: (2022)

Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models
por: Zhao, Qiong-Ya, et al.
Publicado: (2020)

Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
por: Alharthi, Jawaher, et al.
Publicado: (2022)

Therapeutic developments in metabolic dysfunction-associated fatty liver disease
por: Shi, Yiwen, et al.
Publicado: (2022)

Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease
por: Perdomo, Carolina M., et al.
Publicado: (2022)

The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
por: Martín-Mateos, Rosa, et al.
Publicado: (2021)

Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation
por: Yang, Mengmeng, et al.
Publicado: (2023)

Depression and risk of sarcopenia: a national cohort and Mendelian randomization study
por: Zhong, Qian, et al.
Publicado: (2023)

A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease
por: Yang, Chengzhang, et al.
Publicado: (2022)

Parthenolide plays a protective role in the liver of mice with metabolic dysfunction-associated fatty liver disease through the activation of the HIPPO pathway
por: Wang, Weihong, et al.
Publicado: (2021)

Plasma Metabolite Signatures in Male Carriers of Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease
por: Fernandes Silva, Lilian, et al.
Publicado: (2023)

The Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Peripheral Arterial Disease in the Chinese Population
por: Song, Xiao-Hui, et al.
Publicado: (2023)

Low–Normal Thyroid Function Is Not Associated with Either Non-Alcoholic Fatty Liver Disease or with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Zuarth-Vázquez, Julia, et al.
Publicado: (2023)

FTO Polymorphisms are Associated with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Susceptibility in the Older Chinese Han Population
por: Gu, Zhan, et al.
Publicado: (2020)

Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
por: Jia, Yu, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease may be associated with endothelial dysfunction
por: Balta, Sevket, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ud2nlcoq7hg833etuj1pstsob6